News
Couple’s charity aims to support bereaved parents with comfort boxes
A couple who set up a charity to support families experiencing pregnancy after baby loss wants to supply comfort boxes to every hospital in England.
Amneet and Dan Graham, from Gillingham in Kent, set up Willow’s Rainbow Box in 2017 after the birth of their daughter Willow, following a miscarriage the previous year.
The charity provides comfort boxes for women and families who have experienced loss through miscarriage, stillbirth or neonatal death – when a baby dies within the first 28 days of life.
The boxes contain items such as a journal for thoughts, positive affirmations to support wellbeing, cards for healthcare staff to recognise added stress, as well as a crochet pack and links to tutorials.
Ms Graham described her miscarriage as “horrific” and her “worst nightmare”, which left her feeling anxious during her next pregnancy.
“It was just horrific,” she said.
“It was my worst nightmare and I just remember being there and one of the nurses said that I could ‘just try again’ like it was nothing.”
When she became pregnant again she said: “I felt so anxious but didn’t know where to turn. There were groups for baby loss but as I was pregnant, it felt a bit insensitive to go.”
So far, more than 500 boxes have been delivered across England.
“At the moment we deliver England wide but we want to be able to break down barriers so people don’t have to come to us and can get a box from their hospital if they want to,” Ms Graham said.
On 15 September, Dan delivered a box from Medway Maritime Hospital to Royal Victoria Infirmary in Newcastle using only buses, in a journey lasting 17 hours.
“I did my very best to replicate that long and winding road of pregnancy after loss,” he said.
“It was difficult and a tough journey and I hope that I have done people proud.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






